Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer

BMC Cancer

Table 3 Correlation between lipophilic statins user and clinicopathological features

Parameters	Lipophilic statins		p value
Parameters	Non-user (n = 658)	User (n = 61)	p value
Age at operation (years old)			< 0.001
≤ 60	388 (59.0%)	5 (8.2%)
> 60	270 (41.0%)	56 (91.8%)
Tumor size (mm)			0.450
≤ 10.0	196 (29.8%)	21 (34.4%)
> 10.0	462 (70.2%)	40 (65.6%)
Estrogen receptor			0.247
Negative	101 (15.3%)	6 (9.8%)
Positive	557 (84.7%)	55 (90.2%)
Progesterone receptor			0.548
Negative	296 (45.0%)	25 (41.0%)
Positive	362 (55.0%)	36 (59.0%)
HER2			0.228
Negative	595 (90.4%)	58 (95.1%)
Positive	63 (9.6%)	3 (4.9%)
Ki67			0.554
≤ 20%	538 (81.8%)	48 (78.7%)
> 20%	120 (18.2%)	13 (21.3%)
Intrinsic subtype HR + BC			0.367
No	92 (14.0%)	6 (9.8%)
Yes	566 (86.0%)	55 (90.2%)
Intrinsic subtype HR-HER2 + BC			0.107
No	631 (95.9%)	61 (100.0%)
Yes	27 (4.1%)	0 (0.0%)
Intrinsic subtype TNBC			0.992
No	593 (90.1%)	55 (90.2%)
Yes	65 (9.9%)	6 (9.8%)
Lymph vascular invasion			0.504
No	481 (73.1%)	47 (77.0%)
Yes	177 (26.9%)	14 (23.0%)
Hyperlipidemia			< 0.001
No	572 (86.9%)	0 (0.0%)
Yes	86 (13.1%)	61 (100.0%)
Multiple medicine types for hyperlipidemia			0.003
No	653 (99.2%)	58 (95.1%)
Yes	5 (0.8%)	3 (4.9%)
Hydrophilic statins			0.007
Non-user	587 (89.2%)	61 (100.0%)
User	71 (10.8%)	0 (0.0%)
Fibrate			0.862
Non-user	649 (98.6%)	60 (98.4%)
User	9 (1.4%)	1 (1.6%)
Nicotinic acid (tocopherol acetate)			0.055
Non-user	653 (99.2%)	59 (96.7%)
User	5 (0.8%)	2 (3.3%)
Sterol absorption inhibitors (ezetimibe)			0.454
Non-user	652 (99.1%)	61 (100.0%)
User	6 (0.9%)	0 (0.0%)

HER2 Human epidermal growth factor receptor 2. HR + BC Hormone receptor-positive breast cancer (ER+ and/or PgR+). HR-HER2 + BC Human epidermal growth factor receptor 2-enriched breast cancer (ER-, PgR-, and HER2+), TNBC Triple negative breast cancer (ER-, PgR-, and HER2-)

ISSN: 1471-2407